Today: 7 April 2026
Browse Category

NASDAQ:NBIX 7 April 2026

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Soleno Therapeutics Stock Jumps After Neurocrine’s $2.9 Billion Bet on Vykat XR

Neurocrine Biosciences will acquire Soleno Therapeutics for $53 a share in cash, valuing Soleno at $2.9 billion. The deal gives Neurocrine Vykat XR, the only FDA-approved treatment for hyperphagia in Prader-Willi syndrome. Soleno shares last traded at $52.25. The transaction is expected to close within 90 days, pending regulatory and shareholder approval.

Stock Market Today

  • Wall Street Brokers Recommend Strong Buy for Freeport-McMoRan (FCX) Amid Caution
    April 6, 2026, 9:11 PM EDT. Freeport-McMoRan (FCX) holds an average brokerage recommendation (ABR) of 1.37 on a scale from 1 (Strong Buy) to 5 (Strong Sell), reflecting robust confidence with 17 of 23 brokers rating it Strong Buy. This means 73.9% urge investors to buy, signaling positive sentiment. However, studies indicate brokerage recommendations often carry a positive bias due to vested interests, potentially skewing the outlook. Analysts typically issue five Strong Buy recommendations for every Strong Sell. Investors should use these ratings to validate their own research rather than as sole guidance. Tools like the Zacks Rank, an independently audited rating system, provide complementary insights into near-term price prospects. Combining brokerage advice with proprietary rankings can enhance decision-making amid the current bullish brokerage sentiment on FCX.
Go toTop